The global non-muscle invasive bladder cancer market is slated to grow noticeably on the basis of rise in the number of patients suffering from non-muscle invasive bladder cancer along with governments extensively investing in qualitative research pertaining to therapeutics for non-muscle invasive bladder cancer.
The companies operating in the non-muscle invasive bladder cancer market are working toward tapping the unexplored geographies to widen their consumer base. They are also looking forward to upgradation of existing courses of treatment for non-muscle cancer.
Non-muscle invasive bladder cancer (NMIBC) is referred to as cancer located in tissue lining the bladder’s inner surface. The bladder muscle is not playing role over there.
Bladder cancer is more prevalent in men as compared to women. It is also common with aging. It is generally seen in age group of 75-84.
Bladder is where body stores urine prior to leaving it. It is a hollow organ in pelvis with muscular, flexible walls. It can get smaller or bigger as per quantity of urine. Urine reaches the bladder through ureters. They push urine through a tube called urethra.
Growing incidence of non-muscle invasive bladder cancer worldwide is thus driving the non-muscle invasive bladder cancer market.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Research states that bladder cancer is the 13th leading cause of mortality due to cancer. Non-muscle invasive variants represent three-fourth cases and have a higher recurrence rate.
As per the American Cancer Society, 83,190 new-fangled cases of bladder cancer and 16,840 fatalities from bladder cancer have been recorded as of now. It further states that 30% of bladder cancers spread to the deeper layers of bladder wall but are only in bladder.
In the rest of the cases, cancer spreads to adjoining lymph nodes/tissues outside the bladder. In 5% of cases, it spreads to the distant parts of body on being located first.
Need to combat non-muscle invasive bladder cancer is thus contributing to non-muscle invasive bladder cancer market growth.
Bladder cancer is amongst the top 10 most prevalent cancers worldwide. Moreover, it has been reported that majority of newly diagnosed bladder cancer cases are non-muscle invasive bladder cancers (NMIBC). They are characterized by the cancer cells getting confined to the bladder’s inner lining.
The governments across the globe are extensively spending on intravesical anti-cancer therapies such as BCG (live attenuated bacteria meant for stimulating an immune response against the cancer cells) or chemotherapy.
They are also investing in maintenance therapy, so that risk of recurrence can be reduced. Regular cystoscopies are also prescribed in order to monitor regarding recurrence. Additional treatments are initiated on detection of new tumors.
Increase in healthcare spending by governments as mentioned above is thus expanding the non-muscle invasive bladder cancer market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest non-muscle invasive bladder cancer market insights, North America led the non invasive bladder cancer treatment landscape in 2023 and the status quo is expected to remain unchanged during the forecast period. This is attributed to availability of technologically advanced therapeutic and diagnostic methods in the U.S. and conducive reimbursement policies.
Asia Pacific’s significant non-muscle invasive bladder cancer market share is ascribed to rise in incidence of bladder cancer in countries like China and increased accessibility to cutting-edge products and treatments.
Europe’s increasing demand for treatment of muscle invasive bladder cancer is due to growing acceptance of minimally-invasive techniques, rising awareness about early diagnosis and treatment, and increased R&D efforts in this field.
The key participants in the invasive bladder cancer landscape are engaging in inorganic modes of expansion to strengthen their position. For instance, In June 2022, Cipla inked a distribution agreement with Roche Products (India) Pvt. Ltd. in order to expand scope of partnership of including marketing as well as distribution of the latter’s branded oncology drugs
TARIS Biomedical LLC, Merck & Co., Inc., Herantis Pharma Oyj, Viventia Bio Inc., Telormedix SA, Ferring B.V., Altor BioScience Corporation, Novartis AG, Pfizer Inc., GSK plc, Sanofi S.A., Eli Lilly and Company, and AstraZeneca are some of the key players covered in the non-muscle invasive bladder cancer market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.6 Bn |
| Market Forecast (Value) in 2034 | US$ 21.1 Bn |
| Growth Rate (CAGR) | 21.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.6 Bn in 2023
It is projected to grow at a CAGR of 21.4% from 2024 to 2034
Growing prevalence of non-muscle invasive bladder cancer across the globe and increase in overall expenses by the governments in qualitative healthcare spending
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
TARIS Biomedical LLC, Merck & Co., Inc., Herantis Pharma Oyj, Viventia Bio Inc., Telormedix SA, Ferring B.V., Altor BioScience Corporation, Novartis AG, Pfizer Inc., GSK plc, Sanofi S.A., Eli Lilly and Company, and AstraZeneca
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Non-muscle Invasive Bladder Cancer Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Immunotherapy
6.3.2. Chemotherapy
6.3.3. Targeted Therapy
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2020-2034
7.3.1. Low Grade Bladder Cancer
7.3.2. High Grade Bladder Cancer
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Immunotherapy
10.3.2. Chemotherapy
10.3.3. Targeted Therapy
10.4. Market Value Forecast, by Cancer Type, 2020-2034
10.4.1. Low Grade Bladder Cancer
10.4.2. High Grade Bladder Cancer
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Cancer Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Immunotherapy
11.3.2. Chemotherapy
11.3.3. Targeted Therapy
11.4. Market Value Forecast, by Cancer Type, 2020-2034
11.4.1. Low Grade Bladder Cancer
11.4.2. High Grade Bladder Cancer
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Cancer Type
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Immunotherapy
12.3.2. Chemotherapy
12.3.3. Targeted Therapy
12.4. Market Value Forecast, by Cancer Type, 2020-2034
12.4.1. Low Grade Bladder Cancer
12.4.2. High Grade Bladder Cancer
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Cancer Type
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Immunotherapy
13.3.2. Chemotherapy
13.3.3. Targeted Therapy
13.4. Market Value Forecast, by Cancer Type, 2020-2034
13.4.1. Low Grade Bladder Cancer
13.4.2. High Grade Bladder Cancer
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Cancer Type
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment Type, 2020-2034
14.3.1. Immunotherapy
14.3.2. Chemotherapy
14.3.3. Targeted Therapy
14.4. Market Value Forecast, by Cancer Type, 2020-2034
14.4.1. Low Grade Bladder Cancer
14.4.2. High Grade Bladder Cancer
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Cancer Type
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Liminal BioSciences Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. TARIS Biomedical LLC
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Herantis Pharma Oyj
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Viventia Bio Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Telormedix SA
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Ferring B.V.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Altor BioScience Corporation
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Novartis AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Pfizer Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. GSK plc
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Sanofi S.A.
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Eli Lilly and Company
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. AstraZeneca
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
List of Tables
Table 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 2: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 3: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 4: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 5: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 6: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 7: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 8: North America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 9: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 11: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 12: Europe Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 15: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 16: Asia Pacific Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 17: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 19: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 20: Latin America Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 23: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 24: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 1: Global Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 2: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 3: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Treatment Type, 2023
Figure 4: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Cancer Type, 2023
Figure 5: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Cancer Type, 2023
Figure 6: Global Non-muscle Invasive Bladder Cancer Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 7: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Distribution Channel, 2023
Figure 8: Global Non-muscle Invasive Bladder Cancer Market Value Share, by Region, 2023
Figure 9: Global Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 11: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 13: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 14: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 22: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 23: North America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 26: North America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Europe Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 31: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 32: Europe Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 35: Europe Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 40: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 41: Asia Pacific Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 44: Asia Pacific Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Latin America Non-muscle Invasive Bladder Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 49: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 50: Latin America Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 53: Latin America Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 54: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 58: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Cancer Type, 2023 and 2034
Figure 59: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 60: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 62: Middle East & Africa Non-muscle Invasive Bladder Cancer Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-muscle Invasive Bladder Cancer Market
